ArticleBMC public health2025
An evaluation of the severe acute respiratory infection surveillance system in Ireland.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Detecting changepoints in dynamical systems: Modeling time-varying transmission of seasonal influenza.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Evaluation of European severe acute respiratory infection (SARI) surveillance, 27 European countries, 2022/23.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExpansion of the current single hospital site Severe Acute Respiratory Infection (SARI) surveillance programme in Ireland, to create a SARI sentinel hospital network, commenced in 2023. This evaluation aimed to assess the performance of key surveillance system attributes to improve and guide expansion.
methodsA mixed quantitative and qualitative evaluation was conducted from September 2021 to November 2022 using European Centre for Disease Prevention and Control (ECDC) guidance as a framework. SARI surveillance data were analysed to assess completeness and timeliness. Semi-structured focus group discussions and key informant interviews and an online stakeholder questionnaire, evaluated usefulness, simplicity, flexibility and acceptability. Qualitative data were analysed using thematic analysis.
resultsCompleteness of key variables including age and outcome was 100% (n = 747). COVID-19 vaccination status was completed in 89%, completeness of ethnicity data was only 0.6%. Median time from hospitalisation to commencement of data entry was one day (IQR 1-3). Time to receipt of whole genome sequencing (WGS) results was 40 days (IQR 30-61). Themes identified in the qualitative evaluation were the complexity of SARI surveillance, dependence on key individuals and skilled staff. Suggested areas for improvement included process automation and additional resources to improve timeliness and acceptability, particularly during epidemic or pandemic surge periods.
conclusionsThe SARI surveillance system reports complete and timely data. However, improvement in the timeliness of WGS data and recording of vaccination status and equity stratifiers e.g. ethnicity, would strengthen data quality. Priorities for expansion include process automation and adequate resource allocation, to enable reliable SARI surveillance at all times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.